Hariman Laboratories Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 08-12-2024
- Paid Up Capital ₹ 1.00 Cr
as on 08-12-2024
- Company Age 35 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 32.79%
(FY 2022)
- Profit 73.86%
(FY 2022)
- Ebitda 784.59%
(FY 2022)
- Net Worth 14.44%
(FY 2022)
- Total Assets 18.33%
(FY 2022)
About Hariman Laboratories
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Nihchal Israni, Manoj Israni, Mahinder Punwani, and One other member serve as directors at the Company.
- CIN/LLPIN
U70100MH1989PTC053052
- Company No.
053052
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Aug 1989
- Date of AGM
27 May 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Hariman Laboratories?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nihchal Israni  | Whole-Time Director | 01-Jul-2006 | Current |
| Manoj Israni | Director | 21-Jun-2018 | Current |
| Mahinder Punwani | Director | 17-Mar-2021 | Current |
| Suresh Mahalingam | Director | 10-Oct-2017 | Current |
Financial Performance and Corporate Structure Insights of Hariman Laboratories.
Hariman Laboratories Pvt Ltd, for the financial year ended 2022, experienced significant growth in revenue, with a 32.79% increase. The company also saw a substantial improvement in profitability, with a 73.86% increase in profit. The company's net worth Soared by an impressive increase of 14.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hariman Laboratories?
In 2021, Hariman Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Blue Cross Laboratories Private LimitedActive 44 years 5 monthsNihchal Israni and Manoj Israni are mutual person
Nihchal Israni FoundationActive 11 years 4 monthsNihchal Israni, Manoj Israni and 2 more are mutual person
- Niko Management Services Private LimitedActive 34 years 10 months
Manoj Israni and Suresh Mahalingam are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Hariman Laboratories?
Unlock and access historical data on people associated with Hariman Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hariman Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hariman Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
